Tech Center 1600 • Art Units: 1621 1642 1646 1671
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19097573 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING | Final Rejection | Avidity Biosciences, Inc. |
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17611758 | Metabolite Delivery for Modulating Metabolic Pathways of Cells | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 18552478 | ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17999528 | ENGINEERED INTERLEUKIN-10 POLYPEPTIDES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18342898 | MULTIFUNCTIONAL IMMUNE CELL THERAPIES | Final Rejection | Arcellx, Inc. |
| 17818526 | CYCLOPHOSPHAMIDE ANALOGS FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE | Non-Final OA | Becton, Dickinson and Company |
| 16885519 | DIOL COMPOSITION AND POLYESTER | Non-Final OA | Toray Industries, Inc. |
| 17887341 | SCALABLE AND FACILE CELL-MEMBRANE-COATING TECHNOLOGY FOR BOTH POSITIVELY AND NEGATIVELY CHARGED PARTICLES | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18044274 | CpG IMMUNOCONJUGATES FOR CANCER THERAPY | Non-Final OA | University of Southern California |
| 17627613 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | Non-Final OA | Children's Hospital Medical Center |
| 17918947 | OLIGONUCLEOTIDE CONJUGATES AND PREPARATION AND APPLICATIONS THEREOF | Non-Final OA | ACADEMIA SINICA |
| 17093486 | RIBONUCLEOPROTEIN TRANSFECTION AGENTS | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18272050 | ANTI-DLL3 ANTIBODY-DRUG CONJUGATE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 17759139 | VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS | Non-Final OA | University of Miami |
| 18447808 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | Non-Final OA | MSD INTERNATIONAL GMBH |
| 18549837 | ANTIBODIES AGAINST INTEGRIN HETERODIMERS AND USES THEREOF | Non-Final OA | The Governing Council of the University of Toronto |
| 18331966 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | Final Rejection | INNATE PHARMA |
| 18035070 | IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | Randox Laboratories Ltd. |
| 17793005 | ANTI-TROP-2 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | Non-Final OA | GENMAB A/S |
| 17596239 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | Final Rejection | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | Non-Final OA | Navigo Proteins GmbH |
| 18286895 | Applications of GHR-106 Monoclonal Antibody as a GnRH Antagonist | Non-Final OA | VANCOUVER BIOTECH LTD. |
| 18375175 | PREPARATION AND PURIFICATION METHOD OF ANTIBODY DRUG CONJUGATE INTERMEDIATE | Non-Final OA | REMEGEN CO., LTD. |
| 18282696 | ENGINEERED IMMUNE CELLS AND USES THEREOF | Non-Final OA | Nanjing Legend Biotech Co., Ltd. |
| 18258343 | Therapeutic RNA for Treating Cancer | Non-Final OA | BioNTech SE |
| 18548850 | USE OF A PERIOSTIN ANTIBODY FOR TREATING INFLAMMATION, FIBROSIS AND LUNG DISEASES | Non-Final OA | Université d'Orléans |
| 18252818 | PHARMACEUTICAL FORMULATION | Non-Final OA | AstraZeneca UK Limited |
| 18254941 | ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF | Non-Final OA | QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy